Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker

Oncologist

Volumn 18, Issue 7, 2013, Pages 787-794

  Saura, Cristina ^a   Tseng, Ling Ming ^b   Chan, Stephen ^c   Chacko, Raju T ^d   Campone, Mario ^e   Manikhas, Alexy ^f   Nag, Shona M ^g   Leichman, Cynthia G ^h   Dasappa, Lokanatha ⁱ   Fasching, Peter A ^j   De Mendoza, Fernando Hurtado ^k   Fraser Symmans, W ^l   Liu, David ^m   Mukhopadhyay, Pralay ^m   Horak, Christine ^m   Xing, Guan ^m   Pusztai, Lajos ⁿ  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^d CHRISTIAN MEDICAL COLLEGE   (India)

^e CENTRE RENÉ GAUDUCHEAU   (France)

^f Department of Neurosurgery   (Russian Federation)

^g JEHANGIR HOSPITAL   (India)

^h NEW YORK UNIVERSITY   (United States)

ⁱ KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

^j UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^k HOSPITAL NACIONAL EDGARDO REBAGLIATI MARTINS   (Peru)

^l UNIVERSITY OF TEXAS   (United States)

^m BRISTOL MYERS SQUIBB   (United States)

ⁿ YALE CANCER CENTER   (United States)

more..

Author keywords

Biomarker; Early stage breast cancer; Ixabepilone; Neoadjuvant; III Tubulin

Indexed keywords

BETA TUBULIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; IXABEPILONE; PACLITAXEL; ANTINEOPLASTIC AGENT; EPOTHILONE DERIVATIVE; PHARMACOLOGICAL BIOMARKER; TUBB3 PROTEIN, HUMAN; TUBULIN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BONE PAIN; BRAIN METASTASIS; BREAST CANCER; CARDIOPULMONARY INSUFFICIENCY; CLINICAL EVALUATION; CORE BIOPSY NEEDLE; DEATH; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERSENSITIVITY; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; MAJOR CLINICAL STUDY; MASTECTOMY; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUTROPENIA; PARTIAL MASTECTOMY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR VOLUME; BIOSYNTHESIS; BREAST NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPOTHILONES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; TUBULIN;

EID: 84880692967     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0075     Document Type: Article

References (41)

1. Buzdar AU. Preoperative chemotherapy treatment of breast cancer-a review. Cancer 2007;110: 2394-2407.
2. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. Breast Cancer V. 2. 2010. Available at http://www.nccn.org. Accessed September 20, 2010.
3. Maur M, Guarneri V, Frassoldati A et al. Primary systemic therapy in operable breast cancer: Clinical data and biological fall-out. Ann Oncol 2006; 17(Suppl 5):158-164.
4. Gralow JR, Burstein HJ, Wood W et al. Preoperative therapy in invasive breast cancer: Pathologic assessmentandsystemic therapy issues in operable disease. J Clin Oncol 2008;26:814-819.
5. Boughey JC, Peintinger F, Meric-Bernstam F et al. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg 2006;244: 464-470.
6. Rastogi P, Anderson SJ, Bear HD et al. Preoperative chemotherapy: Updaters of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778-785.
7. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-2685.
8. Symmans WF, Peintinger F, Hatzis C et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007;25:4414-4422.
9. Bear HD, Anderson S, Smith RE et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006;24:2019-2027.
10. Smith IC, Heys SD, Hutcheon AW et al. Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456-1466.
11. Heys SD, Hutcheon AW, Sarkar TK; Aberdeen Breast Group. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002;3(Suppl 2):S69-S74.
12. von Minckwitz G, Raab G, Caputo A et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German Breast Group. J Clin Oncol 2005;23:2676-2685.
13. Green MC, Buzdar AU, Smith T et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxelonceevery three weeks. J Clin Oncol 2005;23: 5983-5992.
14. Tommasi S, Mangia A, Lacalamita R et al. Cytoskeleton and paclitaxel-sensitivity in breast cancer: The role of β-tubulins. Int J Cancer 2007;120:2078-2085.
15. Hari M, Yang H, Zeng C et al. Expression of class III β-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton 2003;56:45-65.
16. Kavallaris M, Burkhart CA, Horwitz SB. Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer 1999; 80:1020-1025.
17. Ranganathan S, Benetatos CA, Colarusso PJ et al. Altered beta-tubulin isotype expression in paclitaxel-resistanthumanprostate carcinoma cells. Br J Cancer 1998;77:562-566.
18. Ranganathan S, Dexter DW, Benetatos CA et al. Cloning and sequencing of human βIII-tubulin cDNA: Induction of βIII isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents. Biochim Biophys Acta 1998;1395:237-245.
19. Paradiso A, Mangia A, Chiriatti A et al. Biomarkers predictive for clinical efficacy of Taxolbased chemotherapy in advanced breast cancer. Ann Oncol 2005;16(Suppl 4):iv14-iv19.
20. Sève P, Dumontet C. Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 2008;9:168-175.
21. Tkaczuk KH, Tait NS, Ioffe O et al. Computer assisted quantitative immunofluorescence of tumor tissue marker expression and clinical outcome to chemotherapy in advanced breast cancer patients. Discov Med 2011;12:33-40.
22. Lechleider RJ, Kaminskas E, Jiang X et al. Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies. Clin Cancer Res 2008;14:4378-4384.
23. Hunt JT. Discovery of ixabepilone. Mol Cancer Ther 2009;8:275-281.
24. Lee FYF, Smykla R, Johnston K et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol 2009;63:201-212.
25. Dumontet C, Jordan MA, Lee FF. Ixabepilone: Targeting βIII-tubulin expression in taxaneresistant malignancies. Mol Cancer Ther 2009;8: 17-25.
26. Baselga J, Zambetti M, Llombart-Cussac A et al. Phase II genomics study of ixabepilone as neoadjuvant treatment of breast cancer. J Clin Oncol 2009; 27:526-534.
27. Horak CE, Lee FY, Xu L et al. High β-III tubulin expression in triple-negative (TN) breast cancer (BC) subtype and correlation to ixabepilone response: A retrospective analysis. J Clin Oncol 2009; 27(Suppl 15s):3587a.
28. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-1281.
29. Tan MC, Al Mushawah F, Gao F et al. Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. Am J Surg 2009;198:520-525.
30. Jinno H, Matsuda S, Hayashida T et al. Differential response from neoadjuvant chemotherapy across breast cancer subtypes. J Clin Oncol 2010; 28(Suppl 15S):662a.
31. Straver ME, Rutgers EJ, Rodenhuis S et al. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol 2010;17:2411-2418.
32. Horak CE, Pusztai L, Xing G et al. Biomarker analysis of neoadjuvant doxorubicin/cyclophosph-amide followed by ixabepilone or paclitaxel in earlystage breast cancer. Clin Cancer Res 2013;19:1587-1595.
33. American Cancer Society: Cancer facts and figures, 1996-2006. Available at http://www.cancer.org. Accessed December 2, 2010.
34. Sève P, Mackey J, Isaac S et al. Class III betatubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005; 4:2001-2007.
35. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26:404-413.
36. Bauer JA, Chakravarthy AB, Rosenbluth JM et al. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res 2010;16:681-690.
37. Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-5685.
38. Andre F, Mazouni C, Liedtke C et al. HER2 expression and efficacy of preoperative paclitaxel/ FAC chemotherapy in breast cancer. Breast Cancer Res Treat 2008;108:183-190.
39. Carey LA, Dees EC, Sawyer L et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13: 2329-2334.
40. Pentheroudakis G, Batistatou A, Kalogeras KT et al. Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: A translational Hellenic Cooperative Oncology Group (HeCOG) study. Breast Cancer Res Treat 2011;127:179-193.
41. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006;24:1633-1642.